MedPath

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Phase 3
Active, not recruiting
Conditions
Cystic Fibrosis
Interventions
Registration Number
NCT05153317
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Brief Summary

The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
71
Inclusion Criteria
  • Completed study drug treatment in the parent study (VX20-445-111 Part B, NCT04537793), or had study drug interruption(s) in the parent study, but did not permanently discontinue study drug, and completed study visits up to the last scheduled visit of the Treatment Period of the parent study

Key

Exclusion Criteria
  • History of study drug intolerance in the parent study
  • History of poor compliance with ELX/TEZ/IVA and/or procedures in the parent study

Other protocol defined Inclusion/Exclusion criteria may apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ELX/TEZ/IVAELX/TEZ/IVAParticipants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
ELX/TEZ/IVAIVAParticipants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
Primary Outcome Measures
NameTimeMethod
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)From Day 1 up to Week 196
Secondary Outcome Measures
NameTimeMethod
Absolute Change in Sweat Chloride (SwCl)From Baseline up to Week 192
Absolute Change in Lung Clearance Index (LCI) 2.5From Baseline up to Week 192

Trial Locations

Locations (22)

Banner University of Arizona Medical Center

🇺🇸

Tucson, Arizona, United States

Stanford University

🇺🇸

Palo Alto, California, United States

Children's Hospital of Colorado

🇺🇸

Aurora, Colorado, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

🇺🇸

Chicago, Illinois, United States

Riley Hospital for Children at Indiana University Health

🇺🇸

Indianapolis, Indiana, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

The Children's Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

Washington University School of Medicine / St. Louis Children's Hospital

🇺🇸

Saint Louis, Missouri, United States

NC TraCS Institute - CTRC University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Scroll for more (12 remaining)
Banner University of Arizona Medical Center
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.